187 related articles for article (PubMed ID: 31614005)
1. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
[TBL] [Abstract][Full Text] [Related]
2. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
[TBL] [Abstract][Full Text] [Related]
3. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
[TBL] [Abstract][Full Text] [Related]
5. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
7. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
[TBL] [Abstract][Full Text] [Related]
8. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
Xu WW; Liu DY; Cao YC; Wang XY
Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
10. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
Dijkstra S; Leyten GH; Jannink SA; de Jong H; Mulders PF; van Oort IM; Schalken JA
Prostate; 2014 Sep; 74(12):1222-30. PubMed ID: 25043536
[TBL] [Abstract][Full Text] [Related]
11. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
[TBL] [Abstract][Full Text] [Related]
12. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
Shao L; Zhou Z; Cai Y; Castro P; Dakhov O; Shi P; Bai Y; Ji H; Shen W; Wang J
PLoS One; 2013; 8(3):e58391. PubMed ID: 23554889
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
[TBL] [Abstract][Full Text] [Related]
14. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
[TBL] [Abstract][Full Text] [Related]
15. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
16. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
[TBL] [Abstract][Full Text] [Related]
17. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
Liu B; Gu X; Huang T; Luan Y; Ding X
Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
[TBL] [Abstract][Full Text] [Related]
18. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
